Start Date
November 30, 2021
Primary Completion Date
January 15, 2025
Study Completion Date
January 15, 2025
Ozurdex 0.7mg Ophthalmic Implant
A 0.7mg intravitreal dexamethasone implant will be used for the treatment of posterior, intermediate and panuveitis for minimum of 6 months.
Prednisone
The comparator will be a prednisone taper which is currently the standard care for the uveitis types of focus.
Ottawa Hospital Research Institute - Vision Research Centre, Ottawa
Lead Sponsor
Ottawa Hospital Research Institute
OTHER